-
公开(公告)号:US20200164024A1
公开(公告)日:2020-05-28
申请号:US16695843
申请日:2019-11-26
申请人: NOVARTIS AG
发明人: Karin BRINER , Brian Addison DECHRISTOPHER , Alec Nathanson FLYER , Andrei Alexandrovich GOLOSOV , Philipp GROSCHE , Eugene Yuejin LIU , Justin Yik Ching MAO , Lauren Gilchrist MONOVICH , Tajesh Jayprakash PATEL , Carina Cristina SANCHEZ , Liansheng SU , Lihua YANG , Rui ZHENG
摘要: The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.
-
公开(公告)号:US20220024981A1
公开(公告)日:2022-01-27
申请号:US17296679
申请日:2019-11-26
申请人: Novartis AG
发明人: Alec Nathanson FLYER , Andrei Alexandrovich GOLOSOV , Philipp GROSCHE , Ian LEWIS , Eugene Yuejin LIU , Andreas MARZINZIK , Lauren Gilchrist MONOVICH , Johannes OTTL , Tajesh Jayprakash PATEL , Patrick Crawford REID , Mohindra SEEPERSAUD
摘要: The disclosure relates to inhibitors of PCSK9 useful in the treatment of lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein R1, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, and X13 are described herein.
-
公开(公告)号:US20230089867A1
公开(公告)日:2023-03-23
申请号:US17296895
申请日:2019-11-26
申请人: Novartis AG
发明人: Christopher BECKER , Brian Addison DECHRISTOPHER , Alec Nathanson FLYER , Adam FRIEDMAN , Christian GAMPE , Andrei Alexandrovich GOLOSOV , Philipp GROSCHE , Tyler HARRISON , Qian LIU , Eugene Yuejin LIU, I , Justin Yik Ching MAO , Lauren Gilchrist MONOVICH , Tajesh Jayprakash PATEL , Carina Cristina SANCHEZ , Liansheng SU , Lihua YANG , Rui ZHENG
IPC分类号: C07K7/56
摘要: The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein X1, R1, R2, R3, R4, R5, R6, R6′, R7, R7′, R8, R9, R9′, R10, R11, R12, and n are described herein.
-
公开(公告)号:US20210252103A1
公开(公告)日:2021-08-19
申请号:US17200471
申请日:2021-03-12
申请人: NOVARTIS AG
发明人: Karin BRINER , Brian Addison DECHRISTOPHER , Alec Nathanson FLYER , Andrei Alexandrovich GOLOSOV , Philipp GROSCHE , Eugene Yuejin LIU , Justin Yik Ching MAO , Lauren Gilchrist MONOVICH , Tajesh Jayprakash PATEL , Liansheng SU , Lihua YANG , Rui ZHENG
摘要: The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.
-
5.
公开(公告)号:US20160178610A1
公开(公告)日:2016-06-23
申请号:US14910590
申请日:2014-08-05
IPC分类号: G01N33/50 , A61K31/496
CPC分类号: G01N33/502 , A61K31/4375 , A61K31/444 , A61K31/496 , A61K31/713 , C12N5/0619 , C12N2501/38 , C12N2501/998 , C12N2506/45 , G01N33/5008
摘要: The present application provides a screening method for compounds useful for the treatment of Friedreich's ataxia, and a method for the treatment of Friedreich's ataxia.
摘要翻译: 本申请提供了用于治疗弗里德赖希共济失调的化合物的筛选方法,以及用于治疗弗里德赖希共济失调的方法。
-
-
-
-